|
 |
Li-Fraumeni SyndromeThis page contains recent news articles, when available, and an overview of Li-Fraumeni Syndrome but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.News: Li-Fraumeni Syndrome Nature.comLi–Fraumeni syndrome (LFS) is a genetic predisposition to cancer development at young age. 1, 2, 3 The underlying genetic defect is usually a germline ... DNA mutation likened to lit fuse in kids with cancer syndrome - Feb 15, 2007 CBC.caCertain DNA changes may help predict which patients with an inherited genetic syndrome are at higher risk of developing tumours earlier in life. ... … P53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome - May 8, 2006 RedOrbitAUSTIN, Texas, May 8 /PRNewswire-FirstCall/ -- Introgen Therapeutics' ADVEXIN p53 therapy has been successfully used to treat a Li-Fraumeni Syndrome cancer ... … MDM2 gene contributes to the Li–Fraumeni syndrome and related phe - Feb 16, 2006 Nature.comCorrespondence: Dr LJ van't Veer, Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, The Netherlands. ... Genetic discovery may help detect tumours earlier - Aug 5, 2008 CTV.caTORONTO — Canadian researchers have uncovered a genetic anomaly in people with a higher-than-normal risk of developing cancer that could lead to a blood ... Press Release: Introgen's ADVEXIN p53 Therapy Demonstrates Clinical … - Jun 2, 2006 Pay-Per-View - PR Newswire - HighBeam ResearchIntrogen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer. from PR Newswire. Highbeam Research – FREE Trial. Shortening Chromosomes Cause For Earlier Cancer Onset In Families … - Feb 21, 2007 Medical News Today - Medical News Today (press release)In families with a high incidence of Li-Fraumeni syndrome, the ends of individuals' chromosomes act somewhat like a lit fuse, according to researchers at ... MDM2 promoter variation and age of diagnosis of acute lymphoblastic … - Jul 12, 2005 Nature.comAcute lymphoblastic leukemia (ALL) continues to be the leading cause of childhood cancer, accounting for 25–30% of all diagnoses. Precursor B-cell leukemia, ... Press Release: Gendux AB and Introgen Therapeutics File European … - May 9, 2006 Pay-Per-View - PR Newswire - HighBeam ResearchGendux AB and Introgen Therapeutics File European Orphan Drug Designation for ADVEXIN. from PR Newswire. Highbeam Research – FREE Trial. Introgen says cancer therapy works better for some - Sep 27, 2007 Reuters UKLOS ANGELES, Sept 27 (Reuters) - Introgen Therapeutics Inc INGN.O said on Thursday data from small, mid-stage trials suggested a way to identify cancer ... Press Release: Introgen Therapeutics and Gendux AB Announce Orphan … - Sep 7, 2006 Pay-Per-View - PR Newswire Europe - HighBeam ResearchIntrogen Therapeutics and Gendux AB Announce Orphan Designation for ADVEXIN Therapy in European Union. from PR Newswire Europe. Cancer biology: Sense out of missense - Mar 17, 2005 Nature.comThe p53 protein is notorious for its involvement in many cancers. Studies in mice are helping to clarify how mutations in the human p53 protein produce a ... … /Computed Tomography Screening in Li-Fraumeni Syndrome - Mar 19, 2008 Journal of American Medical Association - Journal of American Medical Association...You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you ... … Orphan Medicinal Product designation, EU (Li-Fraumeni syndrome). - Sep 18, 2006 Pay-Per-View - R & D Focus Drug News - Factiva, from Dow JonesIntrogen and its wholly-owned subsidiary, Gendux, announced on 7 September 2006 that the EMEA has granted ADVEXIN Orphan Medicinal Product designation in ... Introgen Therapeutics Highlights Summary ADVEXIN Data At The Third … - Nov 16, 2007 Medical News Today - Medical News Today (press release)Introgen Therapeutics, Inc. (NASDAQ:INGN) reported summary data from clinical studies of its lead product, ADVEXIN®. These data confirm and extend previous ... Full-Body Scans May Help the Highly Cancer-Prone - Mar 21, 2008 DentalPlans.comFRIDAY, March 21 (HealthDay News) -- Full-body PET/CT scans identified unsuspected, treatable tumors in three of 15 patients with a rare genetic condition ... … p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome.... - May 8, 2006 Pay-Per-View - PR Newswire - HighBeam ResearchIntrogen's ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome. from PR Newswire. Highbeam Research – FREE Trial. Netherlands Corporate News - Gendux meldt acceptatie van ADVEXIN … - Nov 27, 2007 Netherlands Corporate News - Netherlands Corporate News (persbericht)...( BW)(GENDUX-MOLECULAR)(INGN) Gendux Announces Acceptance of Its ADVEXIN Marketing Authorization Application for Review by the EMEA; Gene Therapy Targeting ... Transcription activity is required for p53-dependent tumor suppression - Sep 21, 2009 Nature.comCorrespondence: Dr Y Xu, Division of Biological Sciences, University of California, 9500 Gilman Drive, San Diego, La Jolla, CA 92093-0322, USA. ... Press Release: Introgen Therapeutics and Gendux AB Announce Orphan … - Sep 7, 2006 Pay-Per-View - PR Newswire - HighBeam ResearchIntrogen Therapeutics and Gendux AB Announce Orphan Designation for ADVEXIN Therapy in European Union. from PR Newswire. Highbeam Research – FREE Trial. What Are the Risk Factors for Adrenal Cortical Cancer? - Mar 20, 2009 ACS News CenterA risk factor is anything that changes a person's chance of getting a disease such as cancer. Different cancers have different risk factors. ... … treatment of unresectable CPC in a patient with Li-Fraumeni... - Mar 29, 2005 Pay-Per-View - Science Letter - Factiva, from Dow Jones2005 MAR 29 - (NewsRx.com) -- The successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome has been reported. ... Phase III Biomarker Data Predict Advexin Efficacy in Some Patients - Apr 15, 2008 BioWorld Online - BioWorld OnlineBy Donna Young. Introgen Therapeutics Inc. said that preliminary data of a Phase III trial showed that Advexin, an investigational therapy that targets the ... Press Release: Introgen Therapeutics and Gendux AB Announce … - Oct 31, 2006 Pay-Per-View - PR Newswire Europe - HighBeam ResearchIntrogen Therapeutics and Gendux AB Announce Agreement With European Medicines Agency to File for ADVEXIN Approval Under Exceptional Circumstance Rules. … treatment of unresectable CPC in a patient with Li-Fraumeni... - Mar 28, 2005 Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones2005 MAR 28 - (NewsRx.com) -- The successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome has been reported. ... Sonja Luker cancer bike ride raises $9K - Sep 9, 2009 Atmore AdvanceBy Adam Prestridge. Dogwood Park resident Sonja Luker was overwhelmed with emotions Labor Day at the outpouring of support she and her family received ... Introgen and Gendux Submit First Marketing Authorization Application... - Nov 13, 2007 Free with registration - Business Wire - AccessMyLibrary.comDUBLIN, Ireland & AUSTIN, Texas -- Introgen Therapeutics, Inc. (NASDAQ:INGN) and its subsidiary, Gendux Molecular Limited ("GML"), today announced that a ... Discovery may lead to cancer blood test for high-risk families - Aug 12, 2008 Pay-Per-View - The Record - ProQuest Archiver..."So it would imply that people who have a mutation in this gene and are susceptible to cancer inherently have regions of their DNA which are duplicated or ... … treatment of unresectable CPC in a patient with Li-Fraumeni... - Apr 2, 2005 Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones2005 APR 2 - (NewsRx.com) -- The successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome has been reported. ... Press Release: Introgen Therapeutics and Gendux AB Announce … - Oct 31, 2006 Pay-Per-View - PR Newswire - HighBeam ResearchIntrogen Therapeutics and Gendux AB Announce Agreement With European Medicines Agency to File for ADVEXIN Approval Under Exceptional Circumstance Rules. Introgen Therapeutics Receives European Certification of its US … - Apr 16, 2007 Genetic Engineering News - Genetic Engineering News (press release)Gendux AB and Introgen Therapeutics, Inc. (NASDAQ:INGN) announce today that Introgen has been certified with the United Kingdom's Medicines and Healthcare ... Introgen's Advexin p53 Therapy Demonstrates Clinical Benefit in... - Jun 2, 2006 DG NewsBALTIMORE, MD -- June 2, 2006 -- Introgen Therapeutics, Inc. presented important data describing the beneficial effects and key markers of clinical activity ... Introgen's ADVEXIN Demonstrates Clinical Benefit in Inherited Cancer. - May 30, 2007 Free with registration - Business Wire - AccessMyLibrary.comAUSTIN, Texas -- Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today the publication of data describing the dramatic clinical benefit of its lead ... Genetic discovery may lead to blood test for families with high... - Aug 3, 2008 West Island ChronicleTORONTO - Canadian researchers have uncovered a genetic anomaly in people with a higher-than-normal risk of developing cancer that could lead to a blood ... MRI - Magnetic Resonance Imaging Resource - Sep 12, 2005 spectroscopyNOW.comNMR has allowed German researchers to investigate the cooperative binding of DNA to an important protein involved in suppressing tumour growth in our bodies ... Q1 2006 Introgen Therapeutics, Inc. Earnings Conference Call - Final. - May 10, 2006 Free with registration - Fair Disclosure Wire - AccessMyLibrary.comOPERATOR: Good afternoon. My name is Chastity, and I will be your conference operator today. At this time, I would like to welcome everyone to the Introgen ... DNA: Too Much--or Too Little--Can Be a Bad Thing - Nov 14, 2008 Science NowBy Jennifer Couzin. PHILADELPHIA, PENNSYLVANIA--There's more variety to DNA than you might think: Deletions or additions of genetic material between ... Biotechnology Industry Organization Investor Forum - Final. - Oct 11, 2007 Free with registration - Fair Disclosure Wire - AccessMyLibrary.comUNIDENTIFIED PARTICIPANT: Our next presenting company is Introgen Therapeutics from Austin Texas. Presenting is Senior VP Medical and Scientific Affairs, ... Press Release: Introgen's ADVEXIN p53 Therapy Demonstrates Clinical … - Jun 2, 2006 Pay-Per-View - PR Newswire Europe - HighBeam ResearchIntrogen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer. from PR Newswire Europe. Highbeam Research – FREE Trial. Friends remember UW student Sarah Plants - Feb 27, 2008 washington.eduBy Sara Bruestle. Friends of senior Sarah Plants said she was outgoing, energetic, caring, considerate, genuine, dedicated, passionate and fun. ... Milestone 21 : Nature Milestones in Cancer - Apr 1, 2006 Nature.comThese included genes associated with the childhood cancer Wilms' tumour, Li Fraumeni syndrome, neurofibromatosis, familial adenomatous polyposis, ... Increased risk of malignancies in a population-based study of 818... - Apr 24, 2006 Nature.comSoft-tissue sarcomas (STS) have been associated with various rare cancer syndromes and occur at increased frequencies in survivors of childhood cancer. ... Bride with rare cancer gene opts for mastectomy after wedding - Jul 25, 2007 Times OnlineJoan Crossland is approaching her wedding day with more nervous anxiety than most because only a day after she returns from honeymoon she will have to ... Introgen Therapeutics Reports Second Quarter 2007 Financial and … - Aug 6, 2007 Free with registration - Business Wire - AccessMyLibrary.comCompiled data from other ADVEXIN clinical trials in lung cancer, prostate cancer, Li-Fraumeni Syndrome cancer demonstrating statistically significant ... Introgen's ADVEXIN Molecular Targeted Therapy Is Active in Multiple … - Oct 17, 2006 Free with registration - PR Newswire - AccessMyLibrary.comAUSTIN, Texas, Oct. 17 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. today reported updated data from several clinical studies which demonstrate the ... Pump prices dip in Austin - Jun 3, 2006 Pay-Per-View - Austin American-Statesman - NewsBankAustin area gasoline prices continued to fall this week, dropping to an average of $2.70 a gallon, down four cents from last week, according to the weekly ... Germline CHEK2 mutations and colorectal cancer risk: different... - Jul 5, 2006 Nature.comCorrespondence: Dr C Cybulski, Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. ... Scans spot hidden tumors in rare cancer syndrome - Mar 18, 2008 eurekalert.orgBOSTON--Researchers at Dana-Farber Cancer Institute report that full-body PET/CT scanning detected unsuspected, treatable tumors in 3 of 15 patients with ... Press Release: Gendux AB and Introgen Therapeutics File European … - May 9, 2006 Pay-Per-View - PR Newswire Europe - HighBeam ResearchGendux AB and Introgen Therapeutics File European Orphan Drug Designation for ADVEXIN. from PR Newswire Europe. Highbeam Research – FREE Trial. The miracle worker - Aug 6, 2006 timesonline.co.uk...::nobreak::In 2002 some scientists in Texas who were working with genetically engineered mice made a mistake and got a mighty surprise. ... Introgen Announces New Clinical Data Confirming ADVEXIN(R) Survival … - Dec 12, 2006 Medical News Today - Medical News Today (press release)Introgen Therapeutics, Inc. (Nasdaq: INGN) announced today important new ADVEXIN clinical data and regulatory updates. ADVEXIN delivers the tumor suppressor ... Introgen Therapeutics Reports First Quarter 2006 Financial Results in... - May 10, 2006 $4.95 - PR Newswire - ECNextAUSTIN, Texas, May 10 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. announced today its results for the quarter ended March 31, 2006, ... Press Release: Market for Niche Blockbusters Promises an Attractive … - Feb 25, 2009 Pay-Per-View - PR Newswire Europe - HighBeam ResearchMarket for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan. from PR Newswire Europe. Press Release: Introgen's ADVEXIN Molecular Targeted Therapy Is... - Oct 18, 2006 Pay-Per-View - PR Newswire Europe - HighBeam ResearchIntrogen's ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers; ADVEXIN Regulatory Program Advances.(Clinical report) from PR Newswire Europe. Press Release: Market for Niche Blockbusters Promises an Attractive … - Feb 25, 2009 Pay-Per-View - PR Newswire - HighBeam ResearchMarket for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan. from PR Newswire. Press Release: Frost & Sullivan to Host Analyst Briefing on the... - Jan 26, 2009 Pay-Per-View - PR Newswire Europe - HighBeam ResearchFrost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future?(Industry overview) from PR Newswire ... Chapter 1: The Problem of Extreme Complexity - Jan 24, 2010 New York TimesSome time ago I read a case report in the Annals of Thoracic Surgery. It was, in the dry prose of a medical journal article, the story of a nightmare. ... Introgen Therapeutics, Inc. at BIO CEO & Investor Conference -... - Feb 13, 2008 Free with registration - Fair Disclosure Wire - AccessMyLibrary.comUNIDENTIFIED PARTICIPANT: Good morning. Our next presenting company is Introgen Therapeutics. Introgen Therapeutics is a biopharmaceutical company focused ... Battle met by bravery: The Pleasant family perseveres through trials... - Nov 28, 2006 Free with registration - Baltimore Sun - AccessMyLibrary.comNov. 28--Dressed in a pink nightgown and holding a doll, Talia Pleasant celebrated her third birthday in a hospital room at Johns Hopkins Children's Center, ... drug discovery@nature.com - Jan 2, 2010 Nature.comThe TP53 tumour suppressor is mutated in at least half of all cancers, and other components of the pathway, such as MDM2 and ARF , are mutated in some of ... Soft tissue sarcoma - Sep 12, 2009 CNNSoft tissue sarcomas are cancerous (malignant) tumors that originate in the soft tissues of your body. Soft tissues connect, support and surround other body ... Death at 32 of fashion leader Reza - May 23, 2008 Bournemouth Daily EchoBy Stephen Bailey ». THE Bournemouth founder of fashion company Criminal Clothing has died at 32 from an inherited cancer that blights his family. ... Brain Tumor - Primary - Adults - Symptoms, Diagnosis, Treatment of... - Oct 14, 2009 New York TimesA primary brain tumor is a group (mass) of abnormal cells that start in the brain. This article focuses on primary brain tumors in adults. By DENISE GRADY ... Introgen Plans to Expand Biomarker Database in Phase 3 Trials and... - Dec 20, 2007 Genetic Engineering News - Genetic Engineering News (press release)Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today that upon the recommendation of its external regulatory and clinical advisors, the Company will ... Cancer-struck family joins race - Jun 4, 2005 BBC NewsThree generations of a Wearside family hit by cancer are putting on their running shoes to help others affected by the disease. ... Do We Know What Causes Brain And Spinal Cord Tumors in Children? - Apr 7, 2008 ACS News CenterThe cause of most central nervous system tumors is not fully understood. But researchers have found some of the chemical changes that occur in normal brain ... Bone cancer - Sep 12, 2009 CNN InternationalBone cancer is an uncommon cancer that begins in a bone. Bone cancer can begin in any bone in the body, but it most commonly affects the long bones that ... Rare cancer-causing syndrome found, for the first time, in Singapore - Nov 5, 2007 HinduFindings from the AACR Centennial Conference on Translational Cancer Medicine: From Technology to Treatment Singapore, Nov. 4-8, 2007 ... John L. Shipp, 49 - Mar 23, 2006 $1.95 - Worcester Telegram Gazette - NewsBankNORTHBOROUGH John L. Shipp, 49, of 284 Green St. died March 20, 2006 in Brigham and Women's Hospital in Boston due to lung cancer from Li-Fraumeni Syndrome. ... Atul Gawande's 'Checklist' For Surgery Success - Jan 5, 2010 NPRAtul Gawande is a staff member of Brigham and Women's Hospital and the Dana Farber Cancer Institute. His other books include Better and Complications. ... When mutants gain new powers: news from the mutant p53 field - Aug 20, 2009 Nature.comThe tumour suppressor p53 (encoded by TP53 in humans) functions primarily as a transcription factor, which, upon cellular stress signals, ... Q2 2006 Introgen Therapeutics, Inc. Earnings Conference Call - Part 1. - Aug 9, 2006 Free with registration - America's Intelligence Wire - AccessMyLibrary.comOPERATOR: Good afternoon. My name is Paige, and I will be your conference operator today. At this time, I would like to welcome everyone to the Introgen ... New Clinical Data For ADVEXIN Recurrent Head And Neck Cancer … - May 27, 2006 Medical News Today - Medical News Today (press release)Introgen Therapeutics, Inc. (Nasdaq: INGN) will present data and update the results of clinical trials from ADVEXIN p53 therapy used in recurrent head and ... 'The Checklist Manifesto' - Dec 23, 2009 New York TimesTo handle the complexity, we've split up the tasks among various specialties. But even divvied up, the work can become overwhelming. ... PAID OBITUARIES - Mar 23, 2006 Pay-Per-View - South Florida Sun - Sentinel - ProQuest ArchiverAlaniz Alaniz, Jose A., of Coral Springs, FL passed away on March 21, 2006. Kraeer Funeral Home & Cremation Center.*. Bain Bain, Marion, 72 of Boca Raton, ... EMBRYO TESTING FOR BREAST CANCER. - Apr 26, 2005 Pay-Per-View - Daily Mail - Factiva, from Dow JonesAs well as bowel cancer, the test is used to detect syndromes such as Familial Adenomatous Polyposis and Li Fraumeni Syndrome, linked with cancer, ... Long-term survival and transmission of INI1-mutation via nonpenetrant... - Aug 30, 2007 Nature.comRhabdoid tumour predisposition syndrome (RTPS) is a rare syndrome caused by inheritance of a mutated INI1 gene for which only two multigeneration families ... Study Reveals New Genetic Clues About Cancer - Aug 5, 2008 Washington PostA genetic anomaly in people with a higher-than-normal risk of developing cancer has been identified by Canadian researchers. They said the findings may lead ... Introgen Therapeutics; Introgen Therapeutics has provided details on... - Dec 5, 2006 Pay-Per-View - Life Science Weekly - Factiva, from Dow JonesThis trend article is an immediate alert from NewsRx to identify the most recent news developments at Introgen Therapeutics. Report 1: Introgen Therapeutics ... Factiva Search - Jun 7, 2006 Pay-Per-View - Life Science Weekly - Factiva, from Dow JonesFactiva Search 2.0. BETA. Factiva iWorks™ offers Factiva's exclusive collection of world-class information indexed and optimized for business use. ... Fighting cancer with every stride - Jul 15, 2005 $2.95 - Salt Lake Tribune, The - NewsBankWhen Travis Hess competes in Saturday's Echo Challenge Triathlon near Coalville, it will mark his fifth such race this year. The feat of endurance is made ... MRI promotion causes concern - Apr 1, 2007 $2.95 - Las Vegas Review-Journal - NewsBankBy ANNETTE WELLS. Now that the American Cancer Society has recommended that women at high risk of developing breast cancer undergo annual MRIs in addition ... Box 1 : When mutants gain new powers: news from the mutant p53 field... - Aug 20, 2009 Nature.comLi–Fraumeni syndrome (LFS) is a rare autosomal-dominant highly penetrant cancer predisposition syndrome, proposed by Li and Fraumeni in 1969 (Refs 168, ... Dear Doctor: Screening breast MRI is for high-risk patients - Apr 16, 2008 Pittsburgh Post-Gazette - Pittsburgh Post GazetteQ. I have fibrocystic breasts and a family history of breast cancer. Am I a candidate for screening breast MRI? A. A screening MRI of the breasts is a ... A CHILD'S LAST DAYS - MAKING EACH MOMENT SPECIAL COUPLE … - Jun 20, 2005 $2.95 - Lexington Herald Leader - NewsBankEditor's note: In November 2004, the Herald-Leader told the story of Courtney Carpenter, who had been fighting different types of cancer since infancy. ... Should Mothers Of Young Children Diagnosed With Sarcomas Ask To Get … - Oct 16, 2007 ABC NewsQuestion from Kelbri27: My son died from rhabdomyosarcoma of the prostate 3 yrs ago. According to some studies, mothers of young children diagnosed with ... Gadd45a acts as a modifier locus for lymphoblastic lymphoma - Mar 3, 2005 Nature.com9, 11 Ataxia telangiectasia (AT) and Li Fraumeni syndrome, human syndromes in which ATM function is altered or where only a single copy of the p53 gene is ... New guidelines for MRIs and breast cancer - Mar 28, 2007 earthtimes.orgBy : Health News Editor. ATLANTA, March 28 New US guidelines recommend women with an increased risk of breast cancer receive magnetic resonance imaging ... Go 2 Guy: A rich, full life cut far too short - Feb 14, 2008 Seattle Post-Intelligencer - Seattle Post IntelligencerBy JIM MOORE. A SOON-TO-BE COLLEGE graduate, Sarah Plants wanted to find a job and buy a house with her husband. She also told her mom, "I'd really like to ... Mechanisms of Disease: adrenocortical tumors[mdash]molecular … - Jan 23, 2006 Nature.comMost adrenocortical tumors are benign, unilateral, adrenocortical adenomas that are often discovered incidentally. Adrenocortical cancer is rare. ... Childhood Soft Tissue Sarcoma - Oct 18, 2006 WebMDChildhood soft tissue sarcoma is a disease in which cancer (malignant) cells begin growing in soft tissue in the body. The soft tissues include muscles, ... Gene therapy drug shows potential in cancer trials - Aug 28, 2006 Pay-Per-View - Los Angeles Times - ProQuest ArchiverLast November, Advexin's maker, the Austin, Texas-based Introgen Therapeutics Inc., entered into an alliance with Colgate-Palmolive Co. in New York to ... Association of early life factors and brain tumour risk in a cohort... - Aug 19, 2008 Nature.comCorrespondence: Dr MM Cantwell, Centre for Clinical and Population Sciences, Queen's University Belfast, Mulhouse Building, Royal Group of Hospital, ... Introgen applies to market Advexin in Europe - Nov 13, 2007 Bizjournals.comIntrogen Therapeutics Inc. and its subsidiary, Gendux Molecular Ltd., have submitted a marketing authorization application to the European Medicines Agency ... Lower breast cancer survival in mothers of children with a malignancy:... - Jan 14, 2008 Nature.comAs it is unclear if hereditary factors affect breast cancer survival, this was compared using fertility and cancer registry data, among all women so ... This page contains information on the genetic risk factors for... - Oct 5, 2005 Cancer Research UKThe most important example of a childhood cancer for which there are familial aggregations of cases is retinoblastoma; about 40% of the cases of this tumour ... Birth characteristics and the risk of childhood rhabdomyosarcoma... - Oct 26, 2009 Nature.comTrahair T, Andrews L, Cohn RJ (2007) Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma. ... Breast cancer tools / MRIs used more often for early detection,... - Jan 24, 2008 Pay-Per-View - Richmond Times - Dispatch - ProQuest ArchiverAmong the groups of women considered at higher risk are those with a breast cancer gene mutation (BRCA1 or BRCA2), and women who have a 20 percent to 25 ... Birth characteristics and the risk of childhood rhabdomyosarcoma... - Dec 8, 2009 Nature.comTrahair T, Andrews L, Cohn RJ (2007) Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma. ... Rare cancer-causing syndrome found, for the first time, in Singapore - Nov 4, 2007 eurekalert.orgFindings from the AACR Centennial Conference on Translational Cancer Medicine: From Technology to Treatment Singapore, Nov. 4-8, 2007 ... Background information on Li-Fraumeni Syndrome [When available] Li-Fraumeni syndrome is a rare autosomal dominant hereditary disorder. It is named after Frederick Pei Li and Joseph F. Fraumeni, American physicians who originally described the syndrome. It increases greatly the susceptibility to cancer. The syndrome is a mutation in the p53 tumor suppressor gene, which normally helps control cell growth. Search the web for more resources on Li-Fraumeni Syndrome |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
